ARArti Anushka Ramkisoensing

Arti Anushka Ramkisoensing

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arti Anushka Ramkisoensing has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reference Framework for Implementation of Cardiovascular Imaging in Clinical Trials. A Scientific Statement of the European Association of Cardiovascular Imaging (EACVI) of the ESC

    by Elena Surkova, Alessia Gimelli, Andreas A Giannopoulos, Nina Ajmone Marsan, Andrea Baggiano, Maja Cikes, Anna Baritussio, Arti A Ramkisoensing, Marc R Dweck, Maribel Gonzalez-Del-Hoyo, et al.

    Cardiovascular imaging is integral to modern clinical trials of new pharmaceuticals or devices, enabling refined eligibility, mechanistic insight, and sensitive assessment of treatment response and safety. Potential heterogeneity in data acquisition, analysis, and reporting may affect reproducibility and interpretability across multicentre settings. Rigorous standardization and fit-for-purpose validation of imaging endpoints can improve statistical efficiency, reduce trial duration and cost, and strengthen generated evidence. This Scientific Statement outlines a reference framework for the implementation of cardiovascular imaging in clinical trials. We provide considerations on use of imaging parameters as eligibility criteria in clinical trials, for efficacy signals evaluation, and for assessment of safety. We define principles for clinical, analytical, and operational validation of imaging endpoints, and discuss concepts of minimal clinically important change and minimal detectable change. Additionally, we discuss feasibility considerations for use of cardiovascular imaging endpoints in multicentre clinical trials where differences in equipment and local experience may exist. We delineate standards for harmonization, centralized analysis, and quality control in clinical trials, as well as challenges and opportunities of the integration of artificial intelligence within core-lab workflows. Lastly, we identify gaps in knowledge, challenge of preclinical–clinical translatability and highlight training needs and innovation priorities.


  • Open Access

    Cardiovascular imaging in 2024: review of current research and innovations

    by Andrea Barison, Ana Teresa Timoteo, Saloua El Messaoudi, Sonia Borodzicz-Jazdzyk, Sara Moscatelli, Giulia Elena Mandoli, Christina Luong, Eylem Levelt, Arti Anushka Ramkisoensing, Zahra Raisi-Estabragh, et al.

    Cardiovascular imaging saw significant advancements in 2024, impacting technology, pathophysiology, and clinical applications. This review provides a comprehensive summary of the most impactful research in cardiovascular imaging published in 2024, highlighting technological advancements, as well as research on ischaemic heart disease, valvular heart disease, cardiomyopathies, and heart failure. It emphasizes the crucial role of artificial intelligence, large-scale studies, and technical improvements across echocardiography, cardiovascular magnetic resonance, computed tomography (CT), and nuclear medicine. In the context of ischaemic heart disease, non-invasive imaging strategies improve patient management and reduce invasive coronary angiograms and unnecessary follow-up testing. Computed tomography plaque characterization is a growing area of research, with potential for predicting disease severity, atherosclerosis progression, and clinical outcomes. In valvular heart disease, several imaging studies focused not only on transcatheter treatments for aortic stenosis, mitral regurgitation, and tricuspid regurgitation but also on specific conditions such as mitral valve prolapse and mitral annular disjunction. Finally, for heart failure and cardiomyopathies, imaging plays a vital role in early diagnosis and risk assessment, with newer techniques surpassing traditional methods in providing morpho-function characterization and in predicting long-term outcomes.


  • Open Access

    Cardiovascular imaging research and innovation in 2023

    by Andrea Barison, Ana Teresa Timoteo, Riccardo Liga, Sonia Borodzicz-Jazdzyk, Saloua El Messaoudi, Christina Luong, Giulia Elena Mandoli, Sara Moscatelli, Arti Anushka Ramkisoensing, Sarah Moharem-Elgamal, et al.

    In 2023, cardiovascular imaging has made significant advancements, in terms of technology, pathophysiology, and clinical application. In this review, the most recent research findings in the field of cardiovascular imaging are discussed. Artificial intelligence and large population cohorts, together with several technical improvements, have had a crucial impact on the technological advancements of echocardiography, cardiovascular magnetic resonance, computed tomography (CT), and nuclear medicine. In the field of ischaemic heart disease, it has been demonstrated that appropriate non-invasive imaging strategies improve patients’ management and reduce invasive procedures and the need for additional testing at follow-up. Moreover, improvements in plaque characterization with CT are an expanding field of research with relevant implications for the prediction of disease severity, evolution, and response to treatment. In the field of valvular heart disease, imaging techniques have advanced alongside improvements in transcatheter treatment for aortic stenosis, mitral, and tricuspid regurgitation. Finally, in the field of heart failure and cardiomyopathies, cardiovascular imaging has reinforced its crucial role in early diagnosis and risk evaluation, showcasing advanced techniques that outperform traditional methods in predicting adverse outcomes.


  • Open Access

    ‘Trapped re-entry’ as source of acute focal atrial arrhythmias

    by Tim De Coster, Alexander S Teplenin, Iolanda Feola, Cindy I Bart, Arti A Ramkisoensing, Bram L Den Ouden, Dirk L Ypey, Serge A Trines, Alexander V Panfilov, Katja Zeppenfeld, et al.

    Diseased atria are characterized by functional and structural heterogeneities, adding to abnormal impulse generation and propagation. These heterogeneities are thought to lie at the origin of fractionated electrograms recorded during sinus rhythm (SR) in atrial fibrillation (AF) patients and are assumed to be involved in the onset and perpetuation (e.g. by re-entry) of this disorder. The underlying mechanisms, however, remain incompletely understood. Here, we tested whether regions of dense fibrosis could create an electrically isolated conduction pathway (EICP) in which re-entry could be established via ectopy and local block to become ‘trapped’. We also investigated whether this could generate local fractionated electrograms and whether the re-entrant wave could ‘escape’ and cause a global tachyarrhythmia due to dynamic changes at a connecting isthmus. To precisely control and explore the geometrical properties of EICPs, we used light-gated depolarizing ion channels and patterned illumination for creating specific non-conducting regions in silico and in vitro. Insight from these studies was used for complementary investigations in virtual human atria with localized fibrosis. We demonstrated that a re-entrant tachyarrhythmia can exist locally within an EICP with SR prevailing in the surrounding tissue and identified conditions under which re-entry could escape from the EICP, thereby converting a local latent arrhythmic source into an active driver with global impact on the heart. In a realistic three-dimensional model of human atria, unipolar epicardial pseudo-electrograms showed fractionation at the site of ‘trapped re-entry’ in coexistence with regular SR electrograms elsewhere in the atria. Upon escape of the re-entrant wave, acute arrhythmia onset was observed. Trapped re-entry as a latent source of arrhythmogenesis can explain the sudden onset of focal arrhythmias, which are able to transgress into AF. Our study might help to improve the effectiveness of ablation of aberrant cardiac electrical signals in clinical practice.


    • 1 August 2010
      • Vol. 101  (4) , 255-70

    Young at heart. An update on cardiac regeneration.

    by A M Smits, A A Ramkisoensing, D E Atsma, M-J Goumans

    Cardiovascular disease remains one of the most important causes of mortality. Over the past decades important advances have been made in prevention and treatment of acute complications after myocardial infarction (MI). As a result, the number of patients that acutely die from MI has been reduced. Current treatments can not prevent the loss of cardiac contractility caused by cardiomyocyte death, and therefore patients that do survive MI are prone to develop progressive impaired cardiac function, which may lead to heart failure. Cell-based therapy has been proposed as a potential new therapy to prevent progression to end-stage heart failure by (re)generating contractile tissue in the damaged heart. During the last years many different cell sources have been studied extensively for their cardiomyogenic differentiation capacity in vitro and in vitro. These cells include several populations of cardiac-derived progenitor cells as well as mesenchymal stem cells derived from different sources. It has become clear that not only the origin, but also the "age" of a cell is an important determinant of its plasticity. Therefore, special attention is paid to the difference in developmental state of the cell sources and the consequences for their differentiation capacity and therapeutic applicability. Furthermore, we provide future perspectives for several aspects of cell-based therapy that could be optimized in order to enhance the regeneration of the heart.